🔗 Share this article

As the United States undertakes historic changes to its immunization recommendations, an unexpected name has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by casting doubt on COVID-19 vaccines in the pandemic and has zeroed in on possible deaths following COVID-19 immunization in her recent position at the FDA.

Scheduled Overhauls to Pediatric Immunization Schedule

Health officials were set to unveil sweeping revisions to the childhood vaccine schedule in December, synchronizing the US with the Danish national calendar, sources say – a significant shift that would put the US out of alignment with many the international standard with no evidence for improved outcomes. The announcement has been delayed until the new year.

Rather than the top vaccines chief, Høeg is listed to address the audience at the gathering. She was recently named interim head of the FDA’s CDER, the fifth individual to lead the center this year.

Consolidating Power at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for discontinuing specific childhood immunization guidelines in the US to become more like Denmark, a society with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – typically the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Qualifications

Dr. Høeg has little discernible background in pharmaceutical research, oversight or leadership, which has been typical for previous directors of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in running a major agency. She is not an expert in drug approvals.”

Previous directors of CBER would “understand laws and regulations and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she lacks the sort of resume that former directors who ran CBER have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes numerous off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and other areas, and every single one need to be supervised,” Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant leadership component to the role, which supervises more than 5,000 employees. “It’s a huge leadership role, if you perform it correctly,” Woodcock concluded.

Official Statement and Contentious Initiatives

In response to concerns about Høeg’s fitness for the role and whether this appointment represents more teamwork among agency officials on vaccines, a representative said that the “inquiries stem from flawed presumptions”.

“This background is consistent with the functions of her role,” the representative stated, noting the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial expedited drug-approval program that apparently troubled her former heads. “How are these drugs being picked for this expedited pathway? Who makes the choices?” Dr. Howard said. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed oversight of most medications, with the exception of immunizations.”

Documented Past Work on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, past, Howard observe. She released a study using unconfirmed public submissions to estimate the incidence of heart inflammation following Covid immunization. She advised the Florida top health official Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are riskier than they are.

Included in her “policy goals” for the incoming government included altering regulations for recently developed shots and ending “non-essential” immunizations, she said following the vote on a audio program. At the FDA, Høeg has according to sources floated the idea of barring teenage boys from obtaining Covid vaccinations.

“She is an all-around ideologue who commences with her preconceived notions and reverse-engineers to retrofit the science in a extremely misleading, dishonest manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|